These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32923845)

  • 1. Phase III Precision Medicine Clinical Trial Designs That Integrate Treatment and Biomarker Evaluation.
    Polley MC; Korn EL; Freidlin B
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32923845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker enrichment strategies: matching trial design to biomarker credentials.
    Freidlin B; Korn EL
    Nat Rev Clin Oncol; 2014 Feb; 11(2):81-90. PubMed ID: 24281059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marker Sequential Test (MaST) design.
    Freidlin B; Korn EL; Gray R
    Clin Trials; 2014 Feb; 11(1):19-27. PubMed ID: 24085774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II trial designs with biomarkers.
    Freidlin B; McShane LM; Polley MY; Korn EL
    J Clin Oncol; 2012 Sep; 30(26):3304-9. PubMed ID: 22869885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design.
    Matsui S; Crowley J
    Clin Cancer Res; 2018 Mar; 24(5):994-1001. PubMed ID: 28887317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
    Antoniou M; Jorgensen AL; Kolamunnage-Dona R
    PLoS One; 2016; 11(2):e0149803. PubMed ID: 26910238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine.
    Mandrekar SJ; Sargent DJ
    Chin Clin Oncol; 2014 Jun; 3(2):14. PubMed ID: 25414851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of phase II trial designs for initial marker validation.
    Mandrekar SJ; An MW; Sargent DJ
    Contemp Clin Trials; 2013 Nov; 36(2):597-604. PubMed ID: 23665336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Run-in phase III trial design with pharmacodynamics predictive biomarkers.
    Hong F; Simon R
    J Natl Cancer Inst; 2013 Nov; 105(21):1628-33. PubMed ID: 24096624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy.
    Chen X; Zhang J; Jiang L; Yan F
    BMC Med Res Methodol; 2023 Mar; 23(1):66. PubMed ID: 36941537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-diagnostics co-development in oncology.
    Simon R
    Front Oncol; 2013 Dec; 3():315. PubMed ID: 24392354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
    Antoniou M; Kolamunnage-Dona R; Jorgensen AL
    J Pers Med; 2017 Jan; 7(1):. PubMed ID: 28125057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classification of Companion Diagnostics: A New Framework for Biomarker-Driven Patient Selection.
    Huber C; Friede T; Stingl J; Benda N
    Ther Innov Regul Sci; 2022 Mar; 56(2):244-254. PubMed ID: 34841493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the design and the analysis of stratified biomarker trials in the presence of measurement error.
    Halabi S; Lin CY; Liu A
    Stat Med; 2021 May; 40(12):2783-2799. PubMed ID: 33724513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker based clinical trial design.
    Simon R
    Chin Clin Oncol; 2014 Sep; 3(3):39. PubMed ID: 25841465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Auxiliary variable-enriched biomarker-stratified design.
    Wang T; Wang X; Zhou H; Cai J; George SL
    Stat Med; 2018 Dec; 37(30):4610-4635. PubMed ID: 30221368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subgroup identification for treatment selection in biomarker adaptive design.
    Lu TP; Chen JJ
    BMC Med Res Methodol; 2015 Dec; 15():105. PubMed ID: 26646831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal sequential enrichment designs for phase II clinical trials.
    Zang Y; Yuan Y
    Stat Med; 2017 Jan; 36(1):54-66. PubMed ID: 27640874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of statistical analysis plans in randomize-all phase III trials with a predictive biomarker.
    Matsui S; Choai Y; Nonaka T
    Clin Cancer Res; 2014 Jun; 20(11):2820-30. PubMed ID: 24691019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.